Prescribing information



For patients on ICS monotherapy, ATECTURA® BREEZEHALER® (indacaterol acetate/mometasone furoate inhalation powder) long-acting beta2-agonist (LABA)/inhaled corticosteroid (ICS) (IND/MF) is available in three dierent doses: low, medium and high*.1


How to use the BREEZHALER device

Watch the following video to learn how to use the BREEZHALER.



*ATECTURA BREEZHALER high-dose = IND/MF 150/320 μg (once-daily); ATECTURA BREEZHALER medium-dose = IND/MF 150/160 μg (once-daily); ATECTURA BREEZHALER low-dose = IND/MF 150/80 μg (once-daily).

IND, indacaterol; MF, mometasone furoate; AE, adverse event; SAE, serious adverse event.


  1. ATECTURA BREEZEHALER Summary of Product Characteristics.
ATE20-C003 November 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]